Business
-
Dance Biopharm announced that it has bought back the Asia license for its Dance-501 soft mist inhaled insulin by purchasing the license holder, Harmony Biopharm Limited, from Harmony Plus Holdings Limited (Harmony). Dance said that… Read more . . .
-
Chinese inhaled drug developer and CDMO CF PharmTech has raised $65M in a Series D financing round led by Future Industry Investment Fund (managed by SDIC Fund Management), the company said. The money is to… Read more . . .
-
Hong Kong-based Lee’s Pharmaceutical will advance Windtree Therapeutics up to $3.9 million through the end of October 2017 during negotiations for Lee’s to acquire a controlling interest in Windtree. The first installment of the loan… Read more . . .
-
Adherium has now manufactured and sold 100,000 of its Smartinhaler inhaler monitoring devices, the company has announced. According to Adherium, the Smartinhaler has been sold in more than 40 countries to date. The Smartinhaler platform… Read more . . .
-
Aradigm Corporation has received a 2-year Small Business Initiative Research (SBIR) grant of about $972,000 from the National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) for development of Linhaliq… Read more . . .
-
According to Verona Pharma’s mid-year update, the company is developing MDI and DPI formulations of its RPL554, an inhaled PDE3/PDE4 inhibitor. Nebulized RPL554 is currently in Phase 2 development, and Verona reported positive results from… Read more . . .
-
Innovus Pharmaceuticals says that it has ordered 220,000 units of FlutiCare, an OTC fluticasone propionate nasal spray, in preparation for its US launch in the fourth quarter of 2017. The company says that it will… Read more . . .
-
Endo Pharmaceuticals filed suit against Lupin on July 28, 2017 alleging infringement of patents related to Par’s Nascobal cyanocobalamin nasal spray. The suit was filed in the United States District Court for the Eastern District… Read more . . .
-
Milestone Pharmaceuticals has raised $55 million in a Series C financing round led by Novo Holdings A/S, the company said. The company plans to use the money to fund Phase 3 clinical development of etripamil,… Read more . . .
-
Opiant Pharmaceuticals has announced results from a Phase 1 trial of OPNT002 intranasal naltrexone, which it is developing for the treatment of alcohol use disorder (AUD). According to the company, which recently announced that it… Read more . . .
Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden



